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ABSTRACT 
Leach, Kelly Rebecca. M. S. Department of Neuroscience, Cell Biology, & Physiology, 
Wright State University, 2012. The Use of Forelimb Asymmetry Functional Tests to 




Our laboratory has found increased functional recovery post-stroke with Long Evans rats 
that received a combination of fluoxetine, simvastatin, and vitamin C. The objectives of 
this study were to test that treatment and other drug combinations on Sprague Dawley 
rats, to determine whether Forelimb Asymmetry is a reliable behavioral measure for 
stroke studies, and to determine the most optimal surgical procedure on Sprague Dawley 
rats. There were more significant increases in functional recovery observed on the 
Forelimb Asymmetry than on Montoya Staircase behavioral tests, but there were no 
significant differences between treatment groups and control. The largest number of rats 
that had at least a 20% deficit was in the group that underwent stroke induction through 
injecting 1.5μl endothelin into the strereotactic sites AP (0), ML (-2.5), DV (2.0) and AP 
(1.5), ML (-2.5), DV (2.0) from bregma, which should be utilized in future stroke studies 
with Sprague Dawley rats. 
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Stroke is the number one cause of long-term, serious disability in the United 
States (1). The Framingham Heart Study (FHS) by the National, Heart, Lung, and Blood 
Institute (NHLBI) found these disabilities six months after stroke in ischemic stroke 
survivors at least 65 years old: 50% exhibited some hemiparesis, 30% were unable to 
walk without assistance, 26% needed help with daily living, 19% exhibited aphasia, 35% 
exhibited symptoms of depression, and 26% had to live in a nursing home (1). When 
logistic regression analyses were performed on the data from the FHS, it was found that 
women had higher instances of post-stroke disability than men, but it was due to the 
correlation of greater disability with older age at stroke onset, not gender (2). Six million 
four hundred thousand Americans at least 20 years old have had a stroke (1). About 
795,000 people have a stroke each year, which means on average, every 4 minutes 
someone dies from a stroke (1). The average cost of healthcare for stroke victims in 2010 
was $73.7 billion (1), so there needs to be studies on the long-term healthcare costs for 
ischemic stroke (3). This is a major nationwide issue. Part of the problem is due to the 
fact that the median time between stroke onset and arrival at the emergency room is 3 to 
6 hours; the clot buster drug must be given within 3.5 hours of stroke onset in order to be 
effective, and there is risk of hemorrhage with that treatment (1). Therefore, the only 
treatment option most stroke victims have is rehabilitation, which can be helpful; rats in 
an enriched environment display an increase in progenitor cell proliferation and 
neurogenesis in the subventricular zone (SVZ) and exhibit improved function on the 
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beam-traversing and Montoya Staircase tests (4-6), and rodents that run on the wheel on a 
regular basis show an increase of BDNF receptors, CREB mRNA, and growth-associated 
protein (GAP-43) (7). However, the high instances of disability and death show that 
rehabilitation alone does not completely help a stroke victim regain function. 
NEUROGENESIS POST-ISCHEMIA 
After stroke, studies have shown that neurogenesis occurs to compensate for and 
fix the damage caused by the ischemia. In mice that have undergone an ischemic injury 
of the central nervous system (CNS), there is an increase in neurogenesis from GFAP-
expressing progenitor cells in the SVZ, and new cells migrate to a niche in the peri-
infarct cortex (8). New neurons have been found near the infarct in even human 
postmortem stroke victims (9). There is evidence that brain derived neurotrophic factor 
(BDNF) works as a chemoattractant for immature neurons migrating from the lateral 
ventricles (10-16) After ischemic stroke in rats, BDNF was found in both hemispheres; 
more was found in the hemisphere with the lesion than in the undamaged hemisphere 
(17). At both four and 24 hours after stroke, there was an increase in BDNF activity in 
neurons and ependymal cells in the undamaged hemisphere, whereas an increase in 
BDNF activity was found in microglial cells, endothelial cells of cerebral arterioles, and 
astrocytes in the damaged hemisphere was found during those times (17). At 2 hours 
post-stroke in rats that have undergone middle coronary artery occlusion (MCAO), but 
not at later time points, there was a several-fold increase of the number of BDNF-
immunoreactive cells in the ipsilateral, cingulate, and frontal cortices outside the 
damaged area from the MCAO (18). Those animals in that study with cortical injury 
showed loss of BDNF-immunoreactive fibers in the striatum at 2-24 hours post-stroke, 
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whereas rats with cell damage confined to the striatum exhibited no such change (18). At 
2-16 hours post-stroke, strongly BDNF-immunoreactive fibers were observed along the 
myelinated fascicles medially in the striatum, in the anterior commissure, and in the 
corpus callosum ipsilateral to the MCAO (18). BDNF protein levels were increased by 
133-213% at 2 hours post-stroke in the cingulate and frontal cortices and decreased by 
40% at 24 hours post-stroke in the striatum (18). Enhancing this phenomenon with a 
pharmacological treatment could possibly lower the instances of disability and death after 
ischemic stroke. The question is: what sorts of pharmacological drugs and drug 
combinations would be successful in treating ischemic stroke? 
POSSIBLE THERAPEUTIC EFFECTS OF FLUOXETINE 
Antidepressants may be a valid option; they have been shown to increase the 
number of cells in the hippocampus, promoting neurogenesis, which could help with 
functional recovery (19). Many stroke patients develop depression, and there are many 
studies that indicate that SSRIs may have other benefits, especially fluoxetine. In one 
study, patients were given 20 mg fluoxetine or a placebo daily for 90 days starting 5-10 
days after an ischemic stroke (20). The group that received fluoxetine had more improved 
Fugl-Meyer Motor Scale (FMMS) scores than the group that received placebo; the 
treatment group's score increased by an average of 14.5 points (95% CI [7.3-21.6]), 
whereas the placebo group's score increased by an average of 9.8 points (95% CI [3.4-
16.1]) (20). However, digestive disorders may be a side effect of fluoxetine (20). Still, the 
ability to regain function may outweigh the side effects. One 20 mg dose of fluoxetine 
can increase the activation of the muscles recorded by EMG of the forearm by 21.5% on 
average in stroke patients (21). 
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One way fluoxetine may promote neurogenesis is through BDNF. Daily doses of 
10 mg/kg fluoxetine or desipramine increase the gene expression of BDNF in the dentate 
gyrus (DG) of transgenic mice (15). However, mature BDNF protein is increased more 
rapidly than BDNF mRNA after treatment with 10 mg/kg fluoxetine daily (15). 
Fluoxetine and paroxetine upregulate BDNF, vascular endothelial growth factor (VEGF), 
and VGF mRNA expression, decrease glycogen production, and increase glucose 
utilization and lactate production in Swiss albino mice astrocytes, and these effects are 
not mediated by serotonin (22). 
Chronic treatment with fluoxetine is more effective than acute treatment. For 
example, in one study, rats were given 10 mg/kg fluoxetine once daily for 1 day, 4 days, 
7 days, 14 days, and 21 days; after 4 days of treatment, BDNF mRNA had decreased in 
the hippocampus (by 27% in CA1 and by 15% in CA3) and in the medial habenular (by 
38%) and periventricular thalamic nuclei (by 30%), while after 14 days of treatment, 
BDNF-immunoreactive cells were increased in the hippocampus (by 47% in CA1, by 
61% in CA3, by 53% in the DG, and by 40% in the parietal cortex) and in the medial 
habenular (by 101%) and periventricular thalamic nuclei (by 157%) (13). Also, 
fluoxetine does not promote cell proliferation when it is not a chronic treatment; rats were 
given 5 mg/kg fluoxetine daily for 1, 5, 14, or 28 days, and the number of BrdU-labeled 
cells in the DG was significantly greater in rats that were treated for 14 or 28 days than in 
the rats only treated for 1 or 5 days by about 1000 cells (19). Another way that fluoxetine 
promotes neurogenesis is that it increases cell proliferation, the incidence of cell clusters, 
and number of cells per cell cluster in the DG of stressed rats (10). These positive effects 
of fluoxetine are not always observed; rats treated with fluoxetine as well as 
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rehabilitation exhibited no significant functional recovery (23). However, to administer 
the treatment, 2 surgeries to implant an osmotic pump were performed on these rats (23); 
this could have caused stress in these rats, and stress reduces neurogenesis. 
POSSIBLE THERAPEUTIC EFFECTS OF PAROXETINE 
Another antidepressant that may have therapeutic effects for ischemic stroke 
patients is paroxetine; one study found that 20-40 mg paroxetine taken daily for 6 months 
restores the abnormal N-acetyl aspartate/creatine and choline/creatine ratios in the 
hippocampus and thalamus that are present in stroke survivors with depression (24). 
However, this study had no placebo group, so more research needs to be done to 
elucidate the possible therapeutic effects. Many patients who develop depression after a 
stroke take paroxetine, fluoxetine, or other SSRIs because they are safe to use; tricyclic 
antidepressants and serotonin-norepinephrine reuptake inhibitors can increase blood 
pressure and worsen cardiovascular disease (25). Also, paroxetine taken along with 
aspirin does not inhibit blood clotting (26). Therefore, antidepressants, especially 
fluoxetine and paroxetine, may be a safe and effective therapeutic agent for victims of 
ischemic stroke. 
POSSIBLE THERAPEUTIC EFFECTS OF SIMVASTATIN 
Statins may also be a good option for treatment of the effects of an ischemic 
stroke, especially simvastatin. Statins increase cerebral blood flow, decrease infarct size, 
improve neurological function, and upregulate endothelial nitric oxide synthase (eNOS) 
in mice after an ischemic stroke (27). Simvastatin has much potential as a possible 
therapeutic agent for treating ischemic stroke. For example, one study found that 
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simvastatin increases Notch signaling activity and Presenilin 1 expression, which induces 
arteriogenesis, which could help the healing process of the infarct from an ischemic 
stroke (28). Another study found that simvastatin directly induces angiogenesis by 
increasing the expression of VEGF (16). Simvastatin also increases the expression of 
BDNF, which induces cell proliferation and differentiation in the DG, and simvastatin 
enhances the recovery of spatial learning in rats after a traumatic brain injury (16). 
Simvastatin also lowers oxidative stress by lowering serum 8-isoprostane levels, an 
oxidant (29). 
POSSIBLE THERAPEUTIC EFFECTS OF ATORVASTATIN 
Atorvastatin has some potential as a therapeutic agent for treating or preventing 
ischemic stroke. For example, in one study, patients that had experienced an ischemic 
stroke were given 80 mg atorvastatin or placebo daily for 7 days; more of the patients in 
the atorvastatin group than the placebo group resulted in a disability score of less than 2 
on the modified Rankin scale after treatment (odds ratio, atorvastatin vs placebo, 0.74; 
95% CI [0.26-2.17]) (30). However, this effect was only found with patients that had 
experienced a mild stroke, and there was no difference in infarct size between the 
treatment and placebo groups (30). This lack of effect may be due to the patients only 
being treated for 7 days. One study found that atorvastatin improves function and 
plasticity by increasing levels of VEGF, increasing levels of cyclic guanosine 
monophosphate, angiogenesis, cell proliferation, neurogenesis, and levels of 
synaptophysin in rats after stroke (12). Also, fewer carotid artery plaques are observed 
after subjects are treated with atorvastatin, which could lower their risk factor for stroke 
(31). Atorvastatin also increases latency to seizures and is neuroprotective after stroke, 
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brain injury, and excitotoxic amino acid exposure in rats (32). Two 15mg/kg doses of 
atorvastatin given 12 hours apart lower the risk of hemorrhage by lowering excess 
hemoglobin by the infarct in type 2 diabetic Goto-Kakizaki rats that had undergone 
ischemic stroke through MCAO (33). Also, atorvastatin in combination with ezetimibe 
reduces inflammation and thrombosis in patients with atrial fibrillation, which could help 
prevent stroke (34). Even combining simvastatin with atorvastatin could help the healing 
process; with rats that were treated with both simvastatin and atorvastatin after a 
traumatic brain injury, spatial learning was improved, neurological loss in the CA3 region 
of the hippocampus was reduced, neurogenesis in the DG was observed, and an increased 
rate of angiogenesis was observed (35). 
POSSIBLE PROBLEMS AND SIDE EFFECTS OF STATINS 
However, some studies show a lack of sufficient evidence that statins could be 
helpful in treating survivors of ischemic stroke (36-37). In one study, patients that had 
experienced an acute, ischemic stroke within the previous 96 hours were given either 80 
mg of atorvastatin or placebo daily for 30 days, and the infarct size was measured by 
perfusion computed tomography 3 and 30 days after the start of treatment; the infarct size 
was not significantly altered by atorvastatin: day 3: 454 mm2 (IQR: 107, 1765), day 30: 
462 mm2 (IQR: 43, 1399) (36). A meta-analysis review found that statins do not 
significantly lower mortality in patients that had experienced ischemic stroke or transient 
ischemic attack compared to placebo: pooled odds ratio: 1.51, 95% CI [.6, 3.81] (37). 
Unfortunately, the safety risks of treating with statins are not completely clear. On the 
one hand, it may actually be dangerous to stop treatment with statins after a stroke; statin 
withdrawal in ischemic stroke victims increases the likelihood of death, dependency for 
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daily living, early neurological deterioration, and infarct volume (38-39). In one study, 
ischemic stroke patients who had been treated with statins chronically before stroke were 
given 20 mg atorvastatin daily for 3 months either within 24 hours or 3 days after stroke; 
patients that had to undergo statin withdrawal showed a higher instance of disability 
(modified Rankin score > 2): 60.0% vs 39.0% (p = 0.043), early neurologic deterioration 
(END): 65.2% vs 20.9% (p < 0.0001), and greater infarct volume: 74 vs 26 mL (p = 
0.002) compared with the patients who were treated immediately (38). Statin withdrawal 
was also correlated with 4.66X the risk of death or dependency and 8.67X the risk of 
END after adjusting for age and stroke severity (38). On the other hand, taking statins 
could be dangerous; one major risk of using statins as a chronic treatment is that the 
patient could develop rhabdomyolysis, a disorder where the muscle fibers are broken 
down and released into the bloodstream (37, 40-42). Another risk is that some statins can 
interact with some antidepressants, namely nefazodone, and can cause rhabdomyolysis 
and other severe side effects (41). If used with some caution, simvastatin or atorvastatin 
could help stroke victims regain function. 
POSSIBLE THERAPEUTIC EFFECTS OF VITAMIN C 
High concentrations of vitamin C are found in the brain and other neuroendocrine 
organs (43). Vitamin C works as an antioxidant in the brain (43). It is utilized in many 
enzyme reactions, including catecholamine synthesis, collagen production, and regulation 
of antibodies (43). Vitamin C also works as an antioxidant along with vitamin E by 
improving endothelial function, decreasing levels of superoxide and NAD(P)H oxidase in 
the blood, and increasing levels of the NOS and nitric oxide in the blood (44). Since a 
drop in the level of vitamin C in the brain is observed after reperfusion after ischemic 
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stroke (45), the antioxidants would need to be replenished in the brain. The brain does 
this by enhancing expression and activity of sodium-dependent vitamin C transporter 2 
(46). Vitamin C could therefore have therapeutic effects for patients with ischemic stroke, 
Alzheimer's, Parkinson's, and Huntington's (43). However, there is not much evidence of 
therapeutic effects of vitamin C for ischemic stroke patients. In one study, in stroke 
patients that were treated with vitamin C, their blood level of antioxidants increased, but 
their neurological function was not improved (47). Also, vitamin C can be broken down 
into ascorbate radicals, which is not conducive to healing (48-49). Still, vitamin C may 
have therapeutic effects on ischemic stroke patients when taken in combination with 
other medications, namely antidepressants and statins. 
REASONS FOR THIS STUDY 
Our laboratory has found increased functional recovery post-stroke with Long 
Evans rats that received a combination of fluoxetine, simvastatin, and vitamin C (50), so 
we performed some experiments to elucidate whether these or other medications would 
improve motor function in Sprague Dawley rats that have had an ischemic stroke from 
the injection of endothelin, to test whether Forelimb Asymmetry is a good measure of 
neurological recovery after stroke compared to Montoya Staircase, and to determine the 
most optimal surgical procedure on Sprague Dawley rats to produce a similar infarct size 
and contralateral deficit as the Long Evans rats in the aforementioned study. Forelimb 
Asymmetry is a measure of exploratory behavior in rats and has been used in many 
studies as an indicator of motor function, and Montoya Staircase measures a rat's ability 
to reach for and grasp a sugar pellet and has been used in many studies to measure fine 
motor skills in rats (4, 23, 51-64). In the previous experiment (50) and the experiments 
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detailed in this thesis, we injected endothelin into the cortex instead of performing 
MCAO because the cortical endothelin injection causes as much functional deficit, but 
MCAO has a higher mortality rate (51). The injection also results in a smaller infarct, 
which makes it a more authentic stroke model. Most stroke studies use Long Evans rats 
instead of Sprague Dawley rats because it is easier to produce a long-lasting reduction in 
blood flow in Long Evans rats because Sprague Dawley rats have more collateral blood 
supply in the brain (65). However, it is important to develop a method for studying stroke 
in Sprague Dawley rats because the vasculature of their brain is more analogous to the 
anatomy of humans than the brain anatomy of Long Evans rats, so different stereotactic 
coordinates and amounts of endothelin were tested. The animals were tested on Forelimb 
Asymmetry before and after stroke and were given either vehicle, fluoxetine in 
combination with simvastatin and vitamin C, fluoxetine with simvastatin, fluoxetine in 
combination with atorvastatin and vitamin C, or paroxetine in combination with 
simvastatin and vitamin C in generic or brand name form. Some animals were also tested 
on Montoya Staircase before and after stroke. Here, we show evidence of recovery over 
time but no differences in neurological function between treatment groups on Forelimb 





Endothelin has been successfully used in many studies to induce an ischemic 
stroke in rats (23, 52-53, 66-68). Anesthesia was induced by inhalation of 5% isoflurane. 
The head was shaved, Puralube™ ointment administered to the rodent’s eyes, and the 
animal mounted in a stereotactic apparatus using non-traumatic ear bars. Anesthesia was 
maintained with 2-2.5% isoflurane inhalation during surgery. The surgical site was 
cleaned first with provoiodine, then 70% ethanol, and finally provoiodine and a midline 
incision was made on the top of the head.  Bupivicaine (0.25%) was administered to the 
incision in several drops. A micro-drill (Fine Science Tools), with a 0.9 mm burr drill, 
was used to drill two holes in the skull at the stereotactic sites indicated for each 
experimental group in each experiment. Endothelin (Human and Porcine, EMD 
Chemicals) at a concentration of 400 pmoles/μl (1μl unless otherwise indicated) was 
injected into each site (modified from the procedure of Windle et al. (51)) over the time-
course of 3 minutes. The incision was sutured with Vicryl resorbable sutures and painted 
with provoiodine. No post-operative analgesia (besides bupivicaine) was used, as all have 
been shown to modulate neurogenesis (67-68). All animals were given the drug vehicle 
(4 grams of purchased sugar cookie dough) following surgery to help accustom them to 
the sugar cookie dough. These methods have been modified from the procedure of 




VOLUNTARY ORAL DRUG ADMINISTRATION 
Pharmaceutical drugs (simvastatin, 80 mg tablet; fluoxetine HCl, 20 mg capsule; 
atorvastatin, 80 mg tablet; paroxetine, 20 mg capsule) were used and weights of active 
ingredients were compared to total dry drug weights, to account for any fill compounds. 
The correction factors for fill compounds (10X for simvastatin and atorvastatin and 7.5X 
for fluoxetine HCl and paroxetine) were used to measure out the correct amount of active 
ingredients for each animal. Ascorbic acid (Vitamin C, Fluka) was used in pure form. 
The drug vehicle was 4 grams of purchased sugar cookie dough (Pillsbury). The 
cookie dough was weighed, rounded into a ball and then a depression was made into the 
ball with a push of a finger. The individually weighed drugs were put into the depression 
in the dough ball and rim edges of the depression were brought together and sealed so 
that all the dry chemicals were enclosed in the dough ball. The dough ball was thoroughly 
mixed manually to incorporate all of the chemicals into the dough, and reformed into a 
ball. Each ball either contained no drugs (vehicle) or the designated dosages of drugs for 
each animal assigned to the different drug groups. The dough balls were presented to 
individually housed rats in a glass petri dish around noon each day and left in the cage 
until the next day. Any remaining sugar cookie dough found the next day was counted 
against the complete ingestion of the drug or vehicle (reliability of the voluntary oral 
administration). Any animal that failed to completely eat their vehicle or medicine for a 
total of 3 days or more was excluded from the study. These methods were perfected by a 





FORELIMB ASYMMETRY TEST 
 For this test, animals were placed in a translucent, acrylic cylinder (diameter: 9 
inches) with maple extract painted 14 inches from the bottom for 5 minutes. A video 
camera recorded the animals' movements from a location adjacent and perpendicular to 
the vertical axis of the cylinder, and mirrors were placed on the rear lateral sides of the 
cylinder at an angle to ease identification of forepaws when the animal is turned away 
from the video camera. The animals were tested before the stroke and during various 
times after the stroke. The number and timing of the post-stroke trials will be indicated 
for each experimental group in each experiment. The videos were later viewed on 
QuickTime software in slow motion and scored by an observer blind to treatment 
conditions. The number of times the ipsilateral (right) forepaw and contralateral (left) 
forepaw touched the side of the cylinder as the animal was exploring were counted. A 
touch was counted if any part of the forepaw (even just the tips of the digits) touched the 
side of the cylinder. A paw sliding on the side of the cylinder only counted as one touch; 
the paw had to be lifted in order for another touch to be counted. Simultaneous touching 
of both forepaws was counted as one ipsilateral and one contralateral touch. Proportion of 
ipsilateral (ipsilateral touches/(ipsilateral touches + contralateral touches)) and 
contralateral (contralateral touches/(ipsilateral touches + contralateral touches)) touches 
were calculated for each trial. For the post-stroke trials, deficits for each forepaw were 
calculated by dividing the proportion of touches for the forepaw of interest over the 
proportion of touches for said forepaw in the pre-stroke trial. Therefore, if the quotient 
for an animal approaches 1, it is back to normal pre-stroke performance. If the quotient 
for an animal is less than 1, then it has a functional deficit in that forepaw (e.g. a value of 
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0.6 indicates the animal has 60% of its pre-stroke function, or a functional deficit of 
40%). 
MONTOYA STAIRCASE 
Prior to beginning training on the Montoya Staircase, animals were fasted 
overnight. During the training animals received restricted rat chow, equivalent to 85% of 
their ad lib feed/day. Training took place during the dark phase, with one 15 minute test 
each day for each rat for a maximum of two weeks. Each well of the staircase contained 
three 50 mg sucrose pellets, which had been painted with maple extract and allowed to 
completely dry. The final three days of training were used to establish the pre-stroke 
baseline, with the best performance (total pellets retrieved) used. If more than one trial 
had the same number of total pellets retrieved for the best performance, but different 
performance for the forelimbs, then the results were averaged. Animal weight was not 
allowed to fall below 90% of their ad lib feeding weight during training. The number and 
timing of the post-stroke tests will be indicated for each experimental group in each 
experiment. Post-stroke tests followed an initial overnight fast and testing was for three 
days in the dark phase. Animal rat chow and sugar cookie dough ball for this time period 
totaled 10 grams per day. Any pellets the animal retrieved were not counted against their 
total food in either the training or post-stroke testing. Only animals retrieving at least 9 
pellets in each forepaw by the end of training were included in this part of the functional 
analysis. Animals failing to retrieve any pellets during post-stroke tests were excluded 






All statistical analysis used repeated measures ANOVA with Tukey post-hoc 
analysis unless the data did not pass the Shapiro-Wilk normality test or the equal variance 
test, in which case the Mann-Whitney rank sum test was used. A student's t-test was used 
for comparing 2 sets of data. α < .05 was considered significant. 
ANIMALS AND EXPERIMENTAL DESIGN 
Female Sprague Dawley rats (10-12 months) were housed under 12-hour light/ 
12-hour dark conditions with ad libitum access to food and water outside of training or 
testing for Montoya Staircase, where food was restricted.  All animal procedures were 
approved by the IACUC at Wright State University. To perform the different 
experiments, the rats were designated into five different groups. The experimental 
conditions for each group are summarized in Table 1.                                                                                   
The first group of rats (group 1) were tested in one Forelimb Asymmetry trial to 
test their baseline motor function and then subjected to endothelin-induced cortical 
stroke; 1 μl endothelin was injected in these two stereotactic sites: AP (0), ML (-2.3), DV 
(2.3) and AP (2.3), ML (-2.3), DV (2.3).  Following the stroke, animal groups were given 
vehicle (n = 14) or one of two drug combinations in generic form (5 mg/kg fluoxetine, 
0.5 mg/kg simvastatin, and 20 mg/kg vitamin C (n = 15), or 5 mg/kg paroxetine, 0.5 
mg/kg simvastatin, and 20 mg/kg vitamin C (n = 15)) daily starting 20-26 hours after 
stroke throughout behavioral testing to compare the therapeutic effects of fluoxetine 
versus paroxetine. The animals were tested on Forelimb Asymmetry on post-stroke days 
3, 16, and 31, and these results were compared to the results of the pre-stroke trial as 
indicated previously. One third of the rats from group 1 were euthanized at post-stroke 
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day 10, one third of the rats from group 1 were euthanized on post-stroke day 20, and the 
remaining third from group 1 were euthanized on post-stroke day 32 in order to perform 
Brain Histology (data not shown). Therefore, all of the rats from group 1 were observed 
in the vertical column pre-stroke and post-stroke day 3, two thirds of those rats were 
observed in the vertical column post-stroke day 16, and only one third of those rats were 
observed in the vertical column post-stroke day 31. 
The second group of rats (group 2) were trained for Montoya Staircase retrieval of 
sucrose pellets for two weeks, a trial during the final three days of training was chosen to 
serve as a baseline, and the post-stroke Montoya trials were post-stroke days 8-10 and 29-
31 (data not shown). The animals were then tested in one Forelimb Asymmetry trial to 
test their baseline motor function, and then they were subjected to endothelin-induced 
cortical stroke; 1 μl endothelin was injected in these two stereotactic sites: AP (0), ML   
(-2.5), DV (2.0) and AP (2.3), ML (-2.5), DV (2.0).  Following the stroke, animal groups 
were given vehicle (n = 11) or the drug combination 5 mg/kg fluoxetine, 0.5 mg/kg 
simvastatin, and 20 mg/kg vitamin C in brand name form (n = 12), daily starting 20-26 
hours after stroke throughout behavioral testing. The decision to switch to brand name 
drugs was made because it has been found that the enantiomers of fluoxetine have been 
changed in the generic form of the drug, resulting in more of a non-active metabolite. In 
brand names fluoxetine, there is a larger amount of an active metabolite, which lasts for 
long periods of time. The animals were tested on Forelimb Asymmetry on post-stroke 




The third group of rats (group 3) were trained for Montoya Staircase retrieval of 
sucrose pellets for two weeks, a trial during the final three days of training was chosen to 
serve as a baseline, and the post-stroke Montoya trials were post-stroke days 8-10 and 29-
31 (data not shown). The animals were tested in one Forelimb Asymmetry trial pre-stroke 
to test their baseline motor function, and then they were subjected to endothelin-induced 
cortical stroke; 1 μl endothelin was injected in these two stereotactic sites: AP (0), ML   
(-2.5), DV (2.0) and AP (1.5), ML (-2.5), DV (2.0).  Following the stroke, animal groups 
were given vehicle (n = 11) or one of four drug combinations in generic form (5 mg/kg 
fluoxetine, 0.5 mg/kg atorvastatin, and 20 mg/kg vitamin C (n = 11), 5 mg/kg paroxetine, 
0.5 mg/kg simvastatin, and 20 mg/kg vitamin C (n = 11), (5 mg/kg fluoxetine, 0.5 mg/kg 
simvastatin, and 20 mg/kg vitamin C (n = 12), or 5 mg/kg fluoxetine and 0.5 mg/kg 
simvastatin (n = 11)) daily starting 20-26 hours after stroke throughout behavioral testing 
to compare the therapeutic effects of fluoxetine versus paroxetine and simvastatin versus 
atorvastatin and to determine whether vitamin C is necessary for functional recovery. The 
animals were tested on Forelimb Asymmetry on post-stroke days 3, 16, and 28, and these 
results were compared to the results of the pre-stroke trial as indicated previously. 
The fourth group of rats (group 4) were trained for Montoya Staircase retrieval of 
sucrose pellets for two weeks, a trial during the final three days of training was chosen to 
serve as a baseline, and the only post-stroke Montoya trial was post-stroke days 3-5 (data 
not shown). The animals were tested in one Forelimb Asymmetry trial pre-stroke to test 
their baseline motor function, and then they were subjected to endothelin-induced cortical 
stroke; 1.5 μl endothelin was injected in these two stereotactic sites: AP (0), ML (-2.5), 
DV (2.0) and AP (1.5), ML (-2.5), DV (2.0). Long Evans rats may be more sensitive to 
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the endothelin than Sprague Dawley rats, so the amount of endothelin injected was 
increased in order to produce a larger infarct size. Following the stroke, animal groups 
were given vehicle (n = 5) or the drug combination 5 mg/kg fluoxetine, 0.5 mg/kg 
simvastatin, and 20 mg/kg vitamin C in brand name form (n = 5), daily starting 20-26 
hours after stroke throughout behavioral testing. The animals in group 4 were only tested 
pre-stroke and 3 days post-stroke since they were euthanized at post-stroke day 3 or post-




















DV (2.0)  1.5 μl  FSA  pre‐stroke, PSD 3 
 
Table 1. Experimental conditions of all animal groups.  Under treatments, FSA stands for 5 mg/kg fluoxetine/0.5 mg/kg 
simvastatin/20 mg/kg vitamin C, PSA stands for 5 mg/kg paroxetine/0.5 mg/kg simvastatin/20 mg/kg vitamin C, FAA 
stands for 5 mg/kg fluoxetine/0.5 mg/kg atrorvastatin/20 mg/kg vitamin C, and FS stands for 5 mg/kg fluoxetine/0.5 
mg/kg simvastatin. Under forelimb trials, PSD stands for post-stroke day. Groups 4 and 5 were given brand name 
drugs; the rest were given generic drugs. 
 
EXCLUSIONS 
Any animal failing to completely ingest post-stroke daily medicine or vehicle for 
a total of 3 or more days was completely excluded from the study. Animals failing to 
display at least a 20% functional deficit compared to pre-stroke values in both functional 
tests (post-stroke day 3 in Forelimb Asymmetry; post-stroke days 8-10 in Montoya 
Staircase) were excluded from the study. Any animal failing to retrieve at least 9 pellets 
in each forepaw by the end of training for the Montoya Staircase was excluded from this 
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part of the study only. Animals failing to retrieve any pellets (either paw) in any of the 










86  16 (18.6%)  14 (16.27%)  35 (40.69%)  21 (24.41%) 
 
Table 2. Animals analyzed in each functional test.  This table shows the number of rats that were statistically analyzed 
in each behavioral test (percentage of total are in the parentheses). Only data from rats that exhibited a contralateral 
deficit of at least 20% on post-stroke day 3 on forelimb asymmetry was analyzed for that test and only data from rats 
that exhibited a contralateral deficit of at least 20% on post-stroke days 8-10 on Montoya Staircase was analyzed for 
that test. Any animal failing to retrieve at least 9 pellets in each forepaw by the end of training or to retrieve any pellets 




According to Table 3, using the stereotactic coordinates AP (0), ML (-2.3), DV 
(2.3) and AP (2.3), ML (-2.3), DV (2.3) and rat strain Sprague Dawley, 52.27% of 
animals in group 1 had greater than 20% deficit on post-stroke day 3. The average deficit 











Control  14 6 (42.86%)  8 (57.14%)  6 (42.86%)  3 (21.43%) 
Fluoxetine/Simvastatin/ 
Vit. C  15 9 (60%)  6 (40%)  2 (13.33%)  2 (13.33%) 
Paroxetine/Simvastatin/ 






Table 3.  Forelimb Asymmetry analysis for group 1.  This table shows in the first column the number of rats in each 
treatment group, in the second column the number of rats that exhibited a deficit smaller than 20% on post-stroke day 3 
and were removed from analysis (percentage of total are in the parentheses), and in the subsequent columns the number 
of rats from in each treatment group that provided data from each post-stroke measurement that was statistically 
analyzed (percentage of total are in the parentheses). All rats were observed in the vertical column pre-stroke and post-
stroke day 3, two thirds of those rats were observed in the vertical column post-stroke day 16, and only one third of 
those rats were observed in the vertical column post-stroke day 31. Only data from rats that exhibited a contralateral 




Figure 1.  Forelimb Asymmetry analysis for group 1.  The top graphs depict the functional recovery of the 
contralateral limb ((contralateral touches post-stroke/total touches post-stroke)/(contralateral touches pre-
stroke/total touches pre-stroke)) during the Forelimb Asymmetry trials post-stroke days 3, 16, and 31. The 
graph on the left includes all rats in group 1. The graph on the right includes only the rats that were 
euthanized post-stroke day 32 and were therefore analyzed for all trials. The values on the y-axis are 
proportional, so 1 = 100% recovery, e.g. 0.8 = 80% recovery (20% deficit). When all rats were analyzed, 
there was an overall significant increase in functional recovery at post-stroke day 16 compared to post-stroke 
day 3, but not at post-stroke day 31 (top left), which is not shown. When only rats that were euthanized post-
stroke day 32 were analyzed, there was a significant interaction between treatment group and day of trial in 
functional recovery (top right), which is not shown. The bottom graph depicts the total number of wall 
touches (ipsilateral touches + contralateral touches) for every rat in group 1 during each Forelimb Asymmetry 
trial. # indicates significant difference from post-stroke day 3 (top) or pre-stroke (bottom). 
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In the top panels of Figure 1, data on contralateral paw use and recovery 
following ischemic stroke for group 1 is shown. Again, because the data is showing post-
stroke function divided by pre-stroke function, if the numbers are less than 1, they 
indicate a functional deficit and as the numbers reach 1, they indicate recovery to pre-
stroke values. The data from group 1 for the Forelimb Asymmetry trials passed the 
Shapiro-Wilk normality test and the equal variance test. Two way repeated measures 
ANOVA along with Tukey post hoc testing show that with group 1, when all rats were 
analyzed, there was an overall significant increase in functional recovery at post-stroke 
day 16 compared to post-stroke day 3 (p = .023), but not at post-stroke day 31 (p = .191), 
and when only rats that were euthanized post-stroke day 32 were analyzed, there was a 
significant interaction between treatment group and day of trial in functional recovery (p 
= .043). Also, when only rats that were euthanized post-stroke day 32 were analyzed, 
there was a significant increase in functional recovery in the 
fluoxetine/simvastatin/vitamin C (FSA) group from post-stroke day 3 to post-stroke day 
16 (p = .04), and there was a significant increase in functional recovery in the 
paroxetine/simvastatin/vitamin C (PSA) group from post-stroke day 3 to post-stroke day 
31 (p = .041).  
In the bottom panel of Figure 1, the total number of wall contacts for group 1 in 
the Forelimb Asymmetry test is analyzed to determine whether or not we can have 
confidence in these results. The control group displayed significantly fewer wall touches 
at every trial post-stroke compared to pre-stroke (post-stroke day (PSD) 3: p = .003, PSD 
16: p = .001, PSD 31: p = .009). The reason the decreases in total wall touches of the 2 
treatment groups over the course of the post-stroke testing do not reach significance may 
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be because the data of more rats were statistically analyzed in the control group than in 
each of the 2 treatment groups for post-stroke days 16 and 31. Another explanation may 
be that the treatments may enhance the rats' ability to smell the maple extract, so the rats 
in the treatment groups do not habituate as quickly as the control rats. The lowest number 
of wall contacts is at least 50, which gives confidence in these values. 
According to Table 4, using the stereotactic coordinates AP (0), ML (-2.5), DV 
(2.0) and AP (2.3), ML (-2.5), DV (2.0) and rat strain Sprague Dawley, 43.48% of 
animals had greater than 20% deficit. The average deficit for the control animals in group 
2 that made the deficit criteria was 32.7%. 
Beginning Total  < 20% Deficit  Analyzed 
Control  11 5 (45.45%)  6 (54.54%) 
Fluoxetine/Simvastatin/Vit. C  12 8 (66.67%)  4 (33.33%) 
Total  23 13 (56.52%)  10 (43.48%) 
 
Table 4.  Forelimb Asymmetry analysis for group 2.  This table shows in the first column the number of rats in each 
treatment group, in the second column the number of rats from in each treatment group that exhibited a less than 20% 
deficit on post-stroke day 3 and were removed from analysis (percentage of total are in the parentheses), and in the 
third column the number of rats in each treatment group that provided data that was statistically analyzed (percentage 
of total are in the parentheses). Every rat was observed in the vertical column pre-stroke and on post-stroke days 3, 16, 




Figure 2.  Forelimb Asymmetry analysis for group 2.  The graph on the left depicts the functional recovery of the 
contralateral limb ((contralateral touches post-stroke/total touches post-stroke)/(contralateral touches pre-stroke/total 
touches pre-stroke)) during the Forelimb Asymmetry trials post-stroke days 3, 16, and 28. The values on the y-axis are 
proportional, so 1 = 100% recovery, e.g. 0.8 = 80% recovery (20% deficit). The graph on the right depicts the total 
number of wall touches (ipsilateral touches + contralateral touches) during each Forelimb Asymmetry trial. # indicates 
statistically significant difference from post-stroke day 3. There was also an overall significant decrease in wall touches 
at post-stroke days 3, 16, and 28 compared to pre-stroke. 
 
In the left panel of Figure 2, data on contralateral paw use and recovery following 
ischemic stroke for group 2 is shown. Again, because the data is showing post-stroke 
function divided by pre-stroke function, if the numbers are less than 1, they indicate a 
functional deficit and as the numbers reach 1, they indicate recovery to pre-stroke values. 
The data from group 2 for the Forelimb Asymmetry trials passed the Shapiro-Wilk 
normality test and the equal variance test. Two way repeated measures ANOVA along 
with Tukey post hoc testing show that with group 4, there was a significant increase in 
functional recovery in both the control group and the FSA treatment group at post-stroke 
days 16 and 28 compared to post-stroke day 3 (PSD 16: p < .001, PSD 28: p < .001). 
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In the right hand panel of Figure 2, the total number of wall contacts for group 2 
in the Forelimb Asymmetry test is analyzed. The data from group 2 that measured wall 
touches for the Forelimb Asymmetry trials failed Mauchly’s Test of Sphericity (p < 
.002), so the Greenhouse-Geisser value was used as an adjusted value for Epsilon during 
the ANOVA test. Two way repeated measures ANOVA along with Tukey post hoc 
testing show that there was an overall significant decrease in wall touches at post-stroke 
days 3, 16, and 28 compared to pre-stroke (PSD 3: p = .01, PSD 16: p = .008, PSD 28: p 
= .002). This finding was not unexpected, since it is very typical of rats to get habituated 
to the environment and therefore explore the environment less over time (52-53). The 
lowest number of wall contacts is close to 100, which gives confidence in these values. 
According to Table 5, using the stereotactic coordinates AP (0), ML (-2.5), DV 
(2.0) and AP (1.5), ML (-2.5), DV (2.0) and rat strain Sprague Dawley, 58.93% of 
animals had greater than 20% deficit. The average deficit for the control animals in group 
3 that made the deficit criteria was 29.1%. 
Beginning Total  < 20% Deficit  Analyzed 
Control  11 3 (27.27%)  8 (72.73%) 
Fluoxetine/Atorvastatin/Vit. C  11 5 (45.45%)  6 (54.54%) 
Paroxetine/Simvastatin/Vit. C  11 7 (63.64%)  4 (36.36%) 
Fluoxetine/Simvastatin/Vit. C  12 4 (33.33%)  8 (66.67%) 
Fluoxetine/Simvastatin  11 4 (36.36%)  7 (63.63%) 
Total  56 23 (41.07%)  33 (58.93%) 
 
Table 5.  Forelimb Asymmetry analysis for group 3.  This table shows in the first column the number of rats in each 
treatment group, in the second column the number of rats from in each treatment group that exhibited a less than 20% 
deficit on post-stroke day 3 and were removed from analysis (percentage of total are in the parentheses), and in the 
third column the number of rats from in each treatment group that provided data that was statistically analyzed 
(percentage of total are in the parentheses). Every rat was observed in the vertical column pre-stroke and on post-stroke 





Figure 3.  Forelimb Asymmetry analysis for group 3.  These graphs depict the functional recovery of the contralateral 
limb ((contralateral touches post-stroke/total touches post-stroke)/(contralateral touches pre-stroke/total touches pre-
stroke)) during the Forelimb Asymmetry trials post-stroke days 3, 16, and 28. The values on the y-axis are proportional, 
so 1 = 100% recovery, e.g. 0.8 = 80% recovery (20% deficit). # indicates statistically significant difference from 
paroxetine/simvastatin/vit. C on post-stroke day 3 (top) and fluoxetine/simvastatin/vit. C on post-stroke day 3 (bottom). 
& indicates statistically significant difference from fluoxetine/simvastatin on post-stroke day 3. 
In Figure 3, data on contralateral paw use and recovery following ischemic stroke 
for group 3 is shown. Again, because the data is showing post-stroke function divided by 
pre-stroke function, if the numbers are less than 1, they indicate a functional deficit and 
as the numbers reach 1, they indicate recovery to pre-stroke values. The data from group 
3 for the Forelimb Asymmetry trials passed the Shapiro-Wilk normality test and the equal 
variance test. Two way repeated measures ANOVA along with Tukey post hoc testing 
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show that there was a significant increase in functional recovery in the FSA and 
fluoxetine/simvastatin (FS) treatment groups at post-stroke day 16 compared to post-
stroke day 3 (FSA: p = .001; FS: p = .015), and there was a significant increase in 
functional recovery in the PSA, FSA, and FS treatment groups at post-stroke day 28 
compared to post-stroke day 3 (PSA: p = .025; FSA: p = .005; FS: p < .001). However, 
there were no statistical differences from the control group. In previous tests with Long 
Evans rats, the FSA treatment group had shown significant differences compared to the 
control group (50). 
 
Figure 4.  Forelimb Asymmetry analysis for group 3.  This graph depicts the total number of wall touches (ipsilateral 
touches + contralateral touches) during each Forelimb Asymmetry trial. # and & indicate statistical significance from 
pre-stroke. 
In Figure 4, the total number of wall contacts for group 3 in the Forelimb 
Asymmetry test is analyzed. The control group displayed significantly fewer wall touches 
at post-stroke days 16 and 28 compared to pre-stroke (PSD 16: p = .014, PSD 28: p = 
.016). The fluoxetine/atorvastatin/vitamin C (FAA) treatment group displayed 
significantly fewer wall touches at post-stroke day 28 compared to pre-stroke (p = .043). 
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The FSA treatment group displayed significantly fewer wall touches at all post-stroke 
days compared to pre-stroke (PSD 3: p = .003, PSD 16: p = .018, PSD 28: p = .029). The 
lowest number of wall contacts is at least 50, which gives confidence in these values. 
According to Table 6, using the stereotactic coordinates AP (0), ML (-2.5), DV 
(2.0) and AP (1.5), ML (-2.5), DV (2.0) and rat strain Sprague Dawley while injecting 1.5 
μl of endothelin instead of 1 μl into each stereotactic site, 80% of animals had greater 
than 20% deficit. The average deficit for the control animals in group 4 that made the 






Control  5 0 (0%)  5 (100%) 
Fluoxetine/Simvastatin/Vit. C  5 2 (40%)  3 (60%) 
Total  10 2 (20%)  8 (80%) 
 
 
Table 6.  Forelimb Asymmetry analysis for group 4.  This table shows in the first column the number of rats in each 
treatment group, in the second column the number of rats from in each treatment group that exhibited a less than 20% 
deficit on post-stroke day 3 and were removed from analysis (percentage of total are in the parentheses), and in the 
third column the number of rats in each treatment group that provided data that was statistically analyzed (percentage 
of total are in the parentheses). Every rat was observed in the vertical column pre-stroke and on post-stroke day 3, but 




Figure 5.  Forelimb Asymmetry analysis for group 4.  The graph on the left depicts the functional recovery of the 
contralateral limb ((contralateral touches post-stroke/total touches post-stroke)/(contralateral touches pre-stroke/total 
touches pre-stroke)) during the Forelimb Asymmetry trials post-stroke day 3. The values on the y-axis are proportional, 
so 1 = 100% recovery, e.g. 0.8 = 80% recovery (20% deficit). The graph on the right depicts the total number of wall 
touches (ipsilateral touches + contralateral touches) during each Forelimb Asymmetry trial. # indicates statistical 
significance. 
 
In the left panel of Figure 5, data on contralateral paw use and recovery following 
ischemic stroke for group 4 is shown. Again, because the data is showing post-stroke 
function divided by pre-stroke function, if the numbers are less than 1, they indicate a 
functional deficit and as the numbers reach 1, they indicate recovery to pre-stroke values. 
The data from group 4 for the Forelimb Asymmetry trials passed the Shapiro-Wilk 
normality test and the equal variance test. A student's t-test shows that with group 5, there 
was no significant difference between the control and FSA groups in function at post-
stroke day 3 (t(6) = .188, p = .857). 
In the right hand panel of Figure 5, the total number of wall contacts for group 4 
in the Forelimb Asymmetry test is analyzed. Both groups displayed significantly fewer 
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wall touches at post-stroke day 3 compared to pre-stroke (control: p = .002, FSA: p = 
.007). The lowest number of wall contacts is close to 100, which gives confidence in 
these values. 
 
Figure 6.  Forelimb Asymmetry analysis for all groups.  This graph depicts the mean deficit of controls and percentage 
of animals making the minimum deficit criteria of 20% on post-stroke day 3 for every group in this study and the Long 
Evans rats in our previous study (50). LE stands for the Long Evans rats, Gp1 stands for group 1, Gp2 stands for group 
2, Gp3 stands for group 3, and Gp4 stands for group 4. 
In figure 6, the mean deficit of controls and percentage of animals making the 
minimum deficit criteria of 20% on post-stroke day 3 for every group in this study and 
the Long Evans rats in our previous study (50) are shown. In our previous study, 70% of 
the Long Evans rats made the deficit criteria, and the average deficit for those control 
animals that made the deficit criteria was 37.7% (50). The average deficit of group 1 was 
closest to what was previously found with Long Evans rats at 35.9%. The percentage of 
animals that made deficit criteria in group 4 was larger than what was previously found 
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with Long Evans rats at 80%. The average deficit of group 3 was the smallest at 29.1%. 




The FSA treatment did not work for group 1 (stereotactic coordinates AP (0), ML 
(-2.3), DV (2.3), and AP (2.3), ML (-2.3), DV (2.3)) to allow lasting functional recovery 
compared to the control group. There was a significant increase in functional recovery in 
the FSA treatment group from post-stroke day 3 to post-stroke day 16 which had 
subsided by post-stroke day 31, and there was a significant increase in functional 
recovery in the PSA treatment group from post-stroke day 3 to post-stroke day 31. There 
are many possible reasons for this result. One possible reason could be that paroxetine is 
a better treatment than fluoxetine. However, there were no significant differences 
between treatment groups, particularly from control. Another reason could be that the 
chemical composition of the generic form of fluoxetine may not be reliably effective; the 
enantiomers of fluoxetine have changed in the generic form of the drug, such that it has 
produced more of a non-active metabolite. This study needs to be replicated, utilizing 
brand-name pharmaceuticals instead of generic forms. Another possibility is that the 
fluoxetine is working more quickly; 60% in the FSA group did not make the minimum 
deficit criteria of 20%, whereas only 40% in the PSA group and 42.85% of the control 
group did not make the criteria. There was also an overall significant increase in 
functional recovery at post-stroke day 16 compared to post-stroke day 3, but not at post-
stroke day 31. That is problematic because this is not a typical pattern; the increase in 
function was not long-lasting for the FSA group. This may be due to human error while 
scoring the videos for Forelimb Asymmetry for this group; the videos may need to be 
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scored by a separate party. The average deficit for the control animals in group 1 that 
made the deficit criteria was 35.9%. In our previous study with Long Evans rats, the 
average deficit for the Long Evan control animals that made the deficit criteria was 
37.7% (50). It is a good sign that the percentage of Sprague Dawley rats that made this 
criteria is so close to the percentage of Long Evans rats because it is typically more 
difficult to create a deficit in Sprague Dawley than in Long Evans rats (65). However, only 
52.27% of animals in group 1 made the minimum deficit criteria whereas 70% of the 
Long Evans rats made the deficit criteria (50), so there is probably another stroke-
inducing method that may induce a larger deficit in Sprague Dawley rats. 
In group 2 (stereotactic coordinates AP (0), ML (-2.5), DV (2.0), and AP (2.3), 
ML (-2.5), DV (2.0)), there was a significant increase in functional recovery in both the 
control group and the FSA treatment group observed during the Forelimb Asymmetry 
trials at post-stroke days 16 and 28 compared to post-stroke day 3, but there was no 
significant difference in contralateral deficit between the control and the FSA group. 
These animals were also tested on the Montoya Staircase, which was administered by 
Nicholas Wyatt in our laboratory. There was no significant difference in contralateral 
deficit observed during the Montoya Staircase trials between the two groups. This may be 
due to the small sample of rats that were observed in each test, which could have lowered 
the statistical power of these tests, so the results may have just not reached significance. 
This may be a sufficient explanation for the lack of significant results from the Montoya 
trials, but not for the Forelimb Asymmetry data since there were significant results, just 
not between the groups. This may be due to the fine motor skills involved in grasping the 
sugar pellets, which requires more control of movement than exploring the column 
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during the Forelimb Asymmetry trials. Another possibility is that the animals analyzed on 
the Montoya Staircase may be different animals observed on Forelimb Asymmetry; only 
21.74% of the animals in group 2 made the criteria for both tests, 21.74% of the animals 
only made the criteria for Forelimb Asymmetry, 13.04% of the animals only made the 
criteria for Montoya Staircase, and 43.48% did not make criteria for either test. Why 
would both the control and the treatment groups show functional recovery over time and 
not just the treatment group? This could be due to spontaneous recovery. Studies have 
shown that a brief period of functional recovery occurs in the days following ischemia, 
but this is a false positive result because the neuroprotection is only temporary and is 
reversible (70). It often occurs in stroke-induced animals with small infarct sizes; in 
Sprague Dawley rats that have endured cortical damage from MCAO stroke, functional 
recovery observed in Forelimb Asymmetry is correlated with a smaller infarct size, but 
infarct size is not correlated with scores on reaching tasks (71-72), which could explain 
the difference in results between the two behavioral tests. The average infarct size for the 
treatment group was .8835 mm3, and the average infarct size of the control group was 
.9577 mm3, so we may need to increase the size of the infarct to induce a larger deficit. 
Also, the similar infarct sizes between the control and treatment groups in group 3 may 
be the reason both groups exhibited similar results. Only 43.48% of animals in group 2 
made the minimum deficit criteria, and the average deficit for the control animals in 
group 2 that made the deficit criteria was 32.7%, five percentage points lower than the 
Long Evans rats. There is probably another stroke-inducing method that may induce a 
larger deficit in Sprague Dawley rats. Again, this experiment needs to be replicated with 
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a different surgical procedure, either changing the stereotactic coordinates or increasing 
the dose of endothelin to induce a larger infarct size and therefore a larger deficit. 
The PSA treatment group from group 3 (stereotactic coordinates AP (0), ML       
(-2.5), DV (2.0), and AP (1.5), ML (-2.5), DV (2.0)) exhibited a significant increase in 
functional recovery on Forelimb Asymmetry at post-stroke day 28 compared to post-
stroke day 3, but there were no significant differences between treatment groups, 
particularly with the control group. There was a significant increase in functional 
recovery on Forelimb Asymmetry in both the FS and FSA treatment groups in group 3 at 
post-stroke days 16 and 28 compared to post-stroke day 3. Does that mean vitamin C is 
not necessary for functional recovery? It is possible; in one study, in stroke patients that 
were treated with vitamin C, their blood level of antioxidants increased, but their 
neurological function was not improved (47). However, it could be because the average 
infarct sizes (determined by Saagar Sanghvi) of the two treatment groups were not 
significantly different (FSA = 4.5651 mm3; FS = 2.7686 mm3), and both groups exhibited 
spontaneous recovery. All of the treatment groups had lower percentages of animals 
making the deficit criteria than the control group, which could be a sign that three days of 
treatment are actually causing recovery. The results of the Montoya Staircase show no 
significant effect of treatment group or day of trial on function of contralateral limb, so 
functional recovery was observed on Forelimb Asymmetry, but not on the Montoya 
Staircase. This could be because Forelimb Asymmetry is less objective and more prone to 
human error; judging whether a rat managed to retrieve a pellet out of a container is 
easier than defining what is considered a wall contact. Therefore, these results could be 
false positives. 58.93% of animals in group 3 made the minimum deficit criteria, but the 
36 
 
average deficit for the control animals in group 3 that made the deficit criteria was only 
29.1%. There is probably another stroke-inducing method that may induce a larger deficit 
in Sprague Dawley rats. Again, this experiment needs to be replicated with a different 
surgical procedure, either changing the stereotactic coordinates or increasing the dose of 
endothelin. 
In group 4 (stereotactic coordinates AP (0), ML (-2.5), DV (2.0), and AP (1.5), 
ML (-2.5), DV (2.0), 1.5 μl of endothelin instead of 1 μl), no significant difference 
between the control and FSA treatment groups in function was observed during the 
Forelimb Asymmetry trials at post-stroke day 3, so the switch to brand name drugs may 
not have been successful. That is not certain, however, because only one post-stroke 
behavioral trial was done, so the brand name drugs need to tested on rats that go through 
all post-stroke trials of Forelimb Asymmetry and possibly Montoya Staircase. More 
studies will need to be done to elucidate the specific benefits of the drug combinations 
outlined in these experiments and to determine whether brand name medications are more 
effective than generic medications. The FSA group had 60% of animals making the 
deficit criteria, but all of the animals from the control group made the deficit criteria, 
which could be a sign that three days of treatment are actually causing recovery. Even 
though there was no significant difference between the control and FSA groups in 
function, 80% of animals in group 4 made the minimum deficit criteria, and the average 
deficit for the control animals in group 4 that made the deficit criteria was 32.1%. Even 
though group 1 exhibited the highest average deficit, percentage of rats making the 
minimum deficit criteria in group 4 was even larger than the Long Evans rats, so future 
experiments with Sprague Dawley rats should utilize the stereotactic coordinates used for 
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group 4 while increasing the dosage of endothelin to 1.5 μl to increase the size of the 
infarct. 
The most consistent results from all of the experiments is that the number of wall 
touches significantly decreased over time. This finding was not unexpected since it is 
very typical of rats to get habituated to the environment and therefore explore the 
environment less over time (52-53). Also, there were more significant increases in 
functional recovery observed on the Forelimb Asymmetry than on Montoya Staircase 
behavioral tests. However, while about the same proportion of rats exhibited the 20% or 
larger deficit required for analysis on Forelimb Asymmetry as on the Montoya Staircase, 
the largest deficit seen on the Montoya Staircase was 100%, whereas the largest deficit 
seen on Forelimb Asymmetry was 71.7%. Why, then, were there more significant results 
observed on Forelimb Asymmetry than on Montoya Staircase? This may be due to the 
fine motor skills involved in grasping the sugar pellets, which requires more control of 
movement than exploring the column during the Forelimb Asymmetry trials. Forelimb 
Asymmetry may also be a less sensitive test than the Montoya Staircase and is more 
likely to produce falsely positive results. Therefore, Montoya Staircase may be a more 
reliable method for measuring contralateral deficit than Forelimb Asymmetry. However, 
instead of falsely positive results from spontaneous recovery, it could be that some of the 
drug combinations are working within the first three days post-stroke, particularly the 
fluoxetine/simvastatin/vitamin C combination treatment, so in future studies, we may 
have to begin behavioral observations earlier (around post-stroke day 1) or not start the 
treatment until after the first trial 3 days post-stroke. One problem with these solutions is 
that altering the timing of behavioral observation and treatment could in itself affect the 
38 
 
therapeutic effects of the drugs; beginning behavioral trials that soon after surgery could 
cause stress in the rats, which would in turn prevent neurogenesis, and starting the 
treatments later could be detrimental to the mechanism of the drugs. For example, after 
ischemic stroke in rats, there is an increase in BDNF activity in neurons and ependymal 
cells in the undamaged hemisphere and an increase in BDNF activity in microglial cells, 
endothelial cells of cerebral arterioles, and astrocytes in the damaged hemisphere at both 
four and 24 hours after stroke (17), and at 2 hours post-stroke, but not at later time points, 
there is a large increase of the number of BDNF-immunoreactive cells in the ipsilateral, 
cingulate, and frontal cortices outside the infarct (18), so the lack of BDNF later on could 
prevent the treatment from promoting neurogenesis. We could possibly do an experiment 
where we test whether these changes affect the functional recovery of the animals. 
It is difficult to determine from these studies whether the drug combinations 
tested would be effective at improving neurological function in ischemic stroke patients. 
The low number of animals in each test lowered the statistical power, making absolute 
conclusions about functional recovery problematic. The results for the drug cocktail 
fluoxetine/simvastitin/vitamin C were especially inconsistent; while we have 
demonstrated good evidence of the therapeutic effects of that combination in our previous 
study (50), in the present study, when the FSA combination did effect functional recovery 
over time, there was never any significant difference from control, and, in one instance, 
the effect did not last throughout the testing period. The paroxetine/simvastatin/vitamin C 
and fluoxetine/simvastatin treatment groups did exhibit functional recovery over time; it 
may be tempting to conclude that paroxetine is a more effective treatment and that 
vitamin C is not necessary for functional recovery, but these effects were not significantly 
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different from the control groups, so we cannot make any conclusions about the 
therapeutic effects of these drugs. No recovery was seen with the 
fluoxetine/atorvastatin/vitamin C treatment group, so that drug cocktail may not be an 
effective treatment. 
Overall, these results raise more questions than answer them. Do brand name 
drugs improve recovery from stroke more than generic drugs? Are these drug 
combinations really improving motor function within three days, or are we just observing 
the effects of temporary and reversible spontaneous recovery? Which drug combination 
is most effective? Does Forelimb Asymmetry give too many false positive results? 
However, an effective surgical procedure to induce an ischemic stroke in Sprague 
Dawley rats has been successfully developed, and these questions can be answered in 
future studies utilizing the stereotactic coordinates AP (0), ML (-2.5), DV (2.0), and AP 
(1.5), ML (-2.5), DV (2.0) while injecting 1.5 μl of endothelin in Sprague Dawley rats. 
These studies will hopefully lead to an effective delayed pharmacological treatment that 
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